Great Science. Good Business. Here’s how the device works for you.
Provide your patients with confidence when deciding whether to refer or biopsy a lesion of concern.
The DermaSensor device is not a screening tool—lesions that clearly warrant a biopsy should be biopsied per normal clinical practice. And clearly benign lesions do not require the use of the DermaSensor Device.
The device can be used an unlimited number of times per month, but we estimate the average practice might use the device between 10 and 50 times per month. Therefore, we suggest that practices charge a nominal fee for an optical scan of a lesion with our device which could rule out the need for a more invasive biopsy.
Potential Use Cases
Technology that pays for itself.
No up-front capital expense.
Affordable payment plans.
Specialist skin cancer clinics typically charge an out-of-pocket fee ranging from $95 to $350, on top of the Medicare Rebate for a professional attendance by a general practitioner, recommending annual checks to their patients.